|
Forecast
Period
|
2026-2030
|
|
Market
Size (2024)
|
USD
365.25 Million
|
|
Market
Size (2030)
|
USD
418.42 Million
|
|
CAGR
(2025-2030)
|
2.25%
|
|
Fastest
Growing Segment
|
Anti-emetics
|
|
Largest
Market
|
Kanto
|
Market Overview
Japan
Cancer Supportive Care Market was valued at USD 365.25 Million in 2024 and is
anticipated to project steady growth in the forecast period with a CAGR of 2.25%
through 2030. Vitamin supplements are designed to enhance the regular diet by
providing individuals with the necessary daily nutritional value. Vitamins play
crucial roles in the development and proper functioning of the body, acting as
hormones, coenzymes, and antioxidants. Various factors such as shifting dietary
preferences, busy lifestyles, rising employment rates, and increased awareness
of the health benefits associated with vitamin supplements are expected to
positively influence the market growth.
Due
to hectic schedules, many individuals struggle to maintain a balanced diet,
resulting in nutrient deficiencies. Consequently, there has been a significant
rise in the consumption of vitamin supplements to fulfill daily nutrient and
vitamin requirements, promoting overall health and vitality. Furthermore, the
increasing healthcare expenditure worldwide is anticipated to drive the demand
for vitamin supplements. Additionally, the growing elderly population in both
developed and developing economies presents lucrative opportunities for market
players in the forecast period. The senior population, in particular, relies on
vitamin supplements to meet their dietary needs, promote bone health, and
support overall well-being.
Key Market Drivers
Increasing Cancer Incidence
Increasing
cancer incidence is a critical driver of the growth of the Japan Cancer
Supportive Care Market, impacting various aspects of healthcare demand and
service provision. As cancer incidence rises in Japan, the number of patients
requiring supportive care increases proportionately. In Japan, cancer has
been the leading cause of death since 1981, accounting for one-third of all
fatalities in this nation known for its high life expectancy. According to the
National Cancer Center of Japan, it is estimated that there were 1,019,000 new
cancer cases and 380,400 cancer-related deaths in 2022. This surge in
patient population creates a substantial demand for a wide range of supportive
care services, including pain management, nutritional support, psychological
counseling, and rehabilitation. Cancer treatment often involves prolonged and
intensive therapy, leading to chronic and acute side effects that necessitate
ongoing supportive care. The increasing number of patients enduring these side
effects amplifies the need for comprehensive and sustained supportive care
services.
With
more patients undergoing cancer treatments such as chemotherapy, radiation, and
surgery, there is a heightened need for effective symptom management.
Supportive care therapies that alleviate pain, nausea, fatigue, and other
treatment-related symptoms become essential components of the overall cancer
care plan. The primary goal of supportive care is to enhance the quality of
life for cancer patients. As the incidence of cancer rises, so does the demand
for interventions that help patients manage their symptoms, maintain
functionality, and achieve a better quality of life during and after treatment.
The rising incidence of cancer puts additional strain on healthcare
infrastructure, requiring expansion and enhancement of supportive care services
to meet growing patient needs. This necessitates investment in specialized
facilities, advanced medical equipment, and trained healthcare professionals. The
complexity of cancer treatment and supportive care requires multidisciplinary
teams of oncologists, nurses, pharmacists, nutritionists, and mental health
professionals. The increasing cancer incidence drives the formation and
expansion of these teams to provide comprehensive and coordinated care.
The
growing cancer patient population stimulates research and development of new
supportive care therapies. Pharmaceutical companies and medical device
manufacturers are incentivized to innovate and develop advanced treatments that
address the specific needs of cancer patients, leading to a more robust
pipeline of supportive care products. Increased incidence of cancer leads to
more clinical trials and studies focused on improving supportive care outcomes.
These research efforts contribute to the development of evidence-based
practices and novel therapies that enhance patient care and drive market
growth. Rising cancer incidence correlates with increased healthcare spending
on cancer treatment and supportive care. Government healthcare budgets and
insurance coverage expand to accommodate the growing demand, leading to greater
investment in supportive care services and infrastructure. As the economic
burden of cancer treatment grows, the cost-effectiveness of supportive care
becomes more apparent. Effective supportive care can reduce hospital
admissions, shorten treatment durations, and prevent complications, ultimately
lowering overall healthcare costs and justifying further investment in these
services.
Rising Awareness and Demand
for Quality of Life Improvements
The
rising awareness and demand for quality of life improvements significantly
drive the growth of the Japan Cancer Supportive Care Market. This dynamic is
multifaceted, encompassing patient education, caregiver involvement, healthcare
provider initiatives, and societal shifts towards holistic care.
As
awareness about cancer and its treatment options increases, patients become
more informed about the importance of supportive care in managing symptoms and
enhancing quality of life. Knowledgeable patients are more likely to seek
comprehensive supportive care services, driving demand for a range of
therapies, from pain management to nutritional support. In Japan, the most
prevalent cancers are breast, colorectal (large bowel), prostate, stomach, and
lung cancers. These five types accounted for 60.7% of all new cancer diagnoses
in 2012. Survival rates for these cancers have generally improved since the 1990s.
Notably, the five-year age-standardized survival rate for prostate cancer
increased significantly from 65.7% in 1995-1999 to 86.8% in 2005-2009. In 2012,
Japan recorded the second-highest age-standardized five-year survival rate for
lung cancer globally. Cancer advocacy groups and non-profit organizations
play a pivotal role in educating the public about the benefits of supportive
care. These groups often provide resources, support networks, and informational
campaigns that highlight how supportive care can alleviate treatment side
effects and improve overall well-being, thus encouraging more patients to
utilize these services. As caregivers become more aware of the impact of cancer
treatment on patients’ quality of life, they increasingly advocate for
supportive care interventions. Caregivers, often family members, seek out
information and resources to help manage the emotional, physical, and
psychological challenges faced by cancer patients, driving demand for
supportive care products and services. Caregiver support networks and
educational programs provide valuable information on how to manage side effects
and improve the daily lives of cancer patients. These initiatives help
caregivers make informed decisions about supportive care, contributing to
market growth.
Healthcare
providers are increasingly adopting holistic and patient-centered care models
that emphasize quality of life. This approach involves integrating supportive
care services into standard oncology treatment protocols, ensuring that
patients receive comprehensive care that addresses not only their medical needs
but also their emotional and psychological well-being. The formation of
multidisciplinary teams that include oncologists, nurses, psychologists,
nutritionists, and social workers ensures that all aspects of a patient’s
health are considered. These teams work collaboratively to develop
individualized supportive care plans, enhancing patient outcomes and driving
demand for supportive care services. There is a growing cultural shift towards
valuing holistic and integrative care approaches in Japan. Society increasingly
recognizes that addressing the emotional, psychological, and social aspects of
cancer care is as important as treating the disease itself. This cultural shift
supports the growth of supportive care services that focus on improving
patients’ overall quality of life. Healthcare providers and policymakers are
placing greater emphasis on quality of life metrics when evaluating cancer
treatment outcomes. This focus on holistic measures encourages the adoption of
supportive care services designed to enhance patients’ well-being throughout
their treatment journey.
The
rise of telehealth and remote monitoring technologies allows for continuous
support and symptom management for cancer patients, even from a distance. These
technologies provide patients with easier access to supportive care services,
increasing their utilization and driving market growth. Wearable devices and
mobile health applications that monitor vital signs, track symptoms, and
provide real-time feedback enable patients to manage their condition more
effectively. These tools enhance patients’ ability to maintain quality of life,
leading to higher demand for integrated supportive care solutions. Government
policies and initiatives aimed at improving cancer care often include
provisions for supportive care services. Increased funding and support for
these initiatives help expand access to high-quality supportive care,
contributing to market growth. Enhanced insurance coverage for supportive care
therapies reduces the financial burden on patients, making these services more
accessible. Policies that cover a wide range of supportive care options
encourage patients to seek comprehensive care, driving demand in the market.
Increase in the Aging
Population
The
aging population is a significant driver of growth in the Japan Cancer
Supportive Care Market. This demographic shift impacts healthcare demand and
service provision in various ways, fueling the need for comprehensive
supportive care services. Cancer incidence is significantly higher among older
adults, who are more susceptible to the disease due to age-related changes in
their bodies and cumulative exposure to risk factors. Japan is experiencing
rapid aging, with individuals aged 65 and over representing 27.7% of the total
population as of 2017. This proportion is the highest globally and is projected
to increase steadily, reaching 38.4% by 2065. As Japan's population ages,
the number of elderly cancer patients rises, increasing the demand for
supportive care services tailored to their needs. Older adults often have
multiple comorbidities that complicate cancer treatment and necessitate
comprehensive supportive care. Managing these additional health conditions
alongside cancer requires specialized interventions, driving demand for a wide
range of supportive care services. Elderly cancer patients often require longer
treatment durations and extended recovery periods. Supportive care services
play a crucial role in helping these patients manage chronic symptoms, recover
from surgery, and cope with the long-term effects of cancer treatments, leading
to sustained demand for these services. Recovery and rehabilitation are
critical for elderly patients to regain functionality and improve their quality
of life. The need for rehabilitation services, such as physical therapy and
occupational therapy, grows as the population ages, driving market expansion in
this area.
The
aging population necessitates a focus on geriatric oncology, which involves
comprehensive assessments to understand the unique needs of elderly cancer
patients. These assessments help tailor supportive care plans, ensuring that
interventions are appropriate and effective for older adults, thereby driving
demand for specialized supportive care services. Geriatric oncology requires
multidisciplinary care teams that include oncologists, geriatricians, nurses,
and allied health professionals. These teams work collaboratively to address
the complex needs of elderly cancer patients, promoting the integration of
supportive care into standard treatment protocols and driving market growth. As
the elderly population grows, there is an increasing emphasis on improving the
quality of life for cancer patients. Holistic care approaches that address
physical, emotional, and psychological well-being are essential for elderly
patients, who may experience more severe side effects and complications from
treatment. This focus on quality of life drives demand for comprehensive
supportive care services. Older adults may face unique emotional and
psychological challenges when dealing with cancer. Supportive care services
that provide counseling, mental health support, and social services are crucial
for improving the overall well-being of elderly patients, contributing to
market growth.
Advances
in telehealth and remote monitoring technologies have made it easier to provide
continuous support to elderly cancer patients. These technologies enable
healthcare providers to monitor patients’ health remotely, offer timely
interventions, and ensure that supportive care services are accessible to older
adults, even in remote or underserved areas. The development of assistive
devices and technologies designed for elderly patients, such as mobility aids,
adaptive equipment, and home care solutions, enhances the ability of older
adults to manage their condition and maintain independence. The growing
adoption of these technologies drives the supportive care market. The Japanese
government has implemented policies and initiatives to address the healthcare
needs of an aging society. These policies often include provisions for cancer
care and supportive services, promoting the integration of supportive care into
national healthcare plans and driving market growth. Enhanced insurance
coverage and reimbursement policies for supportive care services make these
interventions more accessible to elderly patients. Financial support from the
government and private insurers reduces the economic burden on patients and
encourages the use of comprehensive supportive care services.
.jpg)
Download Free Sample Report
Key Market Challenges
High Treatment Costs
The
cost of cancer treatment, including supportive care, can be prohibitively
expensive for many patients. While Japan has a robust national health insurance
system, out-of-pocket expenses for advanced supportive care therapies,
medications, and specialized services can still be substantial. This financial
burden may deter patients from seeking comprehensive supportive care, leading
to suboptimal treatment outcomes. High costs also impact healthcare providers
and institutions, which must allocate significant resources to procure advanced
supportive care technologies and therapies. This allocation often necessitates
difficult budgetary decisions, potentially limiting the availability and
accessibility of cutting-edge supportive care options.
Payers
and policymakers are increasingly scrutinizing the cost-effectiveness of new
supportive care treatments and interventions. Demonstrating the value and
long-term benefits of these therapies in terms of patient outcomes and
healthcare savings is essential but can be challenging, potentially hindering
market growth.
Shortage of Specialized
Healthcare Professionals
There
is a notable shortage of specialized healthcare professionals trained in cancer
supportive care, including oncologists, nurses, pharmacists, and allied health
professionals. This shortage is particularly acute in rural and underserved
areas, where access to high-quality supportive care services is limited. Addressing
the workforce gap requires substantial investment in training and education
programs to develop a pipeline of skilled professionals. However, existing
educational and training frameworks may not be adequately equipped to meet the
growing demand for specialized cancer supportive care expertise.
The
demanding nature of cancer care can lead to high levels of burnout among
healthcare providers, exacerbating workforce shortages. Ensuring adequate
support, work-life balance, and professional development opportunities for
healthcare professionals is critical to retaining talent in the field and
maintaining high standards of care.
Regulatory Hurdles
The
regulatory environment in Japan, while rigorous in ensuring patient safety and
treatment efficacy, can be a barrier to the rapid introduction of new
supportive care therapies and technologies. The lengthy and complex approval
processes for new drugs, medical devices, and treatment protocols can delay
market entry and limit the availability of innovative supportive care options. Meeting
regulatory requirements involves substantial compliance and documentation
efforts, which can be resource-intensive for pharmaceutical companies and
healthcare providers. Navigating these regulatory complexities requires
expertise and can pose significant operational challenges, particularly for
smaller companies and institutions.
Securing
reimbursement for new supportive care therapies from national health insurance
can be challenging. Payers require robust evidence of clinical efficacy and
cost-effectiveness, and the negotiation process for reimbursement rates can be
protracted. Delays in securing reimbursement approvals can restrict patient
access to new treatments and impact market growth.
Key Market Trends
Advancements in Personalized
Medicine
Personalized
medicine, which involves tailoring medical treatment to the individual
characteristics of each patient, is revolutionizing cancer care. Genetic
profiling and biomarker testing enable healthcare providers to identify
specific mutations and genetic factors that influence a patient's response to
cancer treatment. This precision allows for the development and administration
of targeted supportive care therapies that are more effective and have fewer
side effects compared to traditional approaches. Personalized supportive care
plans, including optimized dosing regimens and prophylactic treatments, enhance
patient outcomes by minimizing treatment-related complications and improving
quality of life. This trend is driving the adoption of more sophisticated and
individualized supportive care strategies in Japan.
The
trend towards personalized medicine encourages pharmaceutical companies to
invest in research and development of novel supportive care drugs and therapies
tailored to specific patient populations. This innovation pipeline is expected
to introduce advanced supportive care options, further fueling market growth.
Integration of Digital Health
Technologies
The
integration of digital health technologies, such as telemedicine and remote
patient monitoring, is transforming the landscape of cancer supportive care in
Japan. Telemedicine platforms enable cancer patients to consult with their
healthcare providers from the comfort of their homes, ensuring continuous and
timely access to supportive care services, particularly for those in remote or
underserved areas.
Wearable
devices and mobile health applications allow for real-time monitoring of
patients' vital signs, symptoms, and treatment adherence. These tools provide
valuable data that can be used to promptly address complications, manage side
effects, and adjust supportive care interventions as needed. This proactive
approach enhances patient management and improves overall care quality. Advanced
data analytics and artificial intelligence (AI) technologies are being
leveraged to analyze large volumes of patient data, predict treatment outcomes,
and optimize supportive care protocols. AI-driven tools can identify patterns
and trends, enabling healthcare providers to make more informed decisions and
deliver personalized care more efficiently.
Focus on Holistic and
Patient-Centered Care
There
is a growing recognition of the importance of holistic and patient-centered
care in cancer treatment. This approach involves addressing not only the
physical aspects of cancer but also the emotional, psychological, and social
needs of patients. Supportive care services are increasingly incorporating
multidisciplinary teams that include oncologists, nurses, nutritionists,
psychologists, and social workers to provide comprehensive care. Educating
patients about their condition, treatment options, and self-care strategies is
becoming a key component of supportive care. Empowering patients with knowledge
and resources enables them to take an active role in managing their health and
improves adherence to supportive care regimens. This trend is driving the
development of educational programs and resources tailored to the needs of
cancer patients and their families.
Enhancing
the quality of life for cancer patients is a central goal of supportive care.
This involves not only managing symptoms and side effects but also addressing
issues such as pain management, nutritional support, mental health, and social
support. The focus on improving quality of life is leading to the adoption of
innovative therapies and interventions that prioritize patient well-being and
satisfaction.
Segmental Insights
Therapeutics Class Insights
Based
on Therapeutics Class, the Granulocyte Colony Stimulating
Factor (G-CSF) segment emerged as the dominant in the market for Japan Cancer
Supportive Care in 2024. G-CSF is pivotal in the supportive care of cancer
patients undergoing chemotherapy. Chemotherapy often results in neutropenia, a
significant reduction in white blood cells, increasing infection risk. G-CSF
stimulates the bone marrow to produce more white blood cells, thereby reducing
the duration and severity of neutropenia. This makes it an indispensable
therapeutic class in oncology supportive care. The efficacy of G-CSF in
preventing and managing neutropenia has been well-documented through numerous
clinical trials and real-world studies. Its ability to reduce the incidence of
febrile neutropenia, decrease hospitalization rates, and allow for the maintenance
of chemotherapy dose intensity is widely recognized. The established safety
profile of G-CSF further bolsters its adoption among healthcare providers.
Due
to its proven benefits, G-CSF is extensively prescribed by oncologists in
Japan. It is a standard component of chemotherapy regimens for various cancers,
including breast, lung, and lymphoma. The consistent use of G-CSF across
multiple cancer types and stages significantly contributes to its dominance in
the cancer supportive care market. Japan’s advanced healthcare infrastructure
ensures the effective delivery and monitoring of G-CSF therapy. Hospitals and
oncology centers are equipped with the necessary resources to administer G-CSF
and manage any potential side effects, ensuring optimal patient outcomes. This
infrastructure supports the widespread use of G-CSF, further solidifying its
market position.
Continuous
innovation in the G-CSF segment has led to the development of long-acting
formulations, such as pegfilgrastim, which require less frequent dosing
compared to traditional short-acting G-CSF. These advancements improve patient
compliance and convenience, making G-CSF therapy more attractive to both
patients and healthcare providers. The availability of biosimilars has also
increased accessibility and affordability, driving market growth. The Japanese
regulatory framework supports the use of G-CSF by ensuring rigorous evaluation
of its safety and efficacy. Approval of new G-CSF formulations and biosimilars
is streamlined, allowing for timely access to these therapies. Additionally,
favorable reimbursement policies make G-CSF therapy financially viable for
patients, encouraging its widespread use. These factors collectively contribute
to the growth of this segment.
Download Free Sample Report
Regional Insights
Kanto
emerged as the dominant in the Japan Cancer Supportive Care market in 2024,
holding the largest market share in terms of value. The Kanto region,
encompassing Tokyo and its surrounding prefectures, is one of the most populous
areas in Japan. The high population density translates into a higher absolute
number of cancer cases, necessitating extensive supportive care services. This
demand drives the market growth as healthcare providers and institutions seek
to address the needs of a large patient base.
Kanto
is home to some of the most advanced healthcare facilities in Japan. These
institutions are equipped with state-of-the-art technology and are staffed by
highly trained medical professionals. The presence of such facilities ensures
that cancer patients receive comprehensive supportive care, including pain
management, nutritional support, psychological counseling, and rehabilitation
services. The high quality of care provided in this region enhances patient
outcomes and drives market growth. The Kanto region houses numerous leading
medical institutions and cancer treatment centers, such as the National Cancer
Center Hospital and the University of Tokyo Hospital. These institutions not
only provide cutting-edge cancer treatments but also offer specialized
supportive care services. Their reputation for excellence attracts patients
from across Japan, further solidifying Kanto's dominance in the market.
The
Kanto region is a hub for medical research and innovation. Numerous
pharmaceutical companies and research institutions are based here, driving
advancements in cancer treatment and supportive care. Ongoing research
initiatives and clinical trials contribute to the development of new supportive
care therapies and improve existing ones, ensuring that patients in Kanto have
access to the latest and most effective care options. The economic prosperity of the Kanto region
allows for significant investment in healthcare infrastructure and services.
Both public and private sectors allocate substantial resources to enhance
cancer care facilities, procure advanced medical equipment, and train
healthcare professionals. This financial capability ensures the continuous
improvement and expansion of supportive care services, catering to the growing
needs of cancer patients.
Recent Developments
- In
March 2024- AstraZeneca has announced that Capivasertib (Truqap) in combination
with fulvestrant (Faslodex) has been approved in Japan for the treatment of
adult patients with unresectable or recurrent hormone receptor (HR)-positive,
HER2-negative breast cancer that contains PIK3CA, AKT1, or PTEN alterations,
following progression on previous endocrine therapy.
Key Market Players
- Amgen,
Inc.
- Merck & Co., Inc.
- Johnson & Johnson Services, Inc.
- Heron Therapeutics, Inc.
- Novartis AG
- GSK plc
- F. Hoffmann-La Roche Ltd.
- Helsinn Healthcare SA
|
By
Therapeutics Class
|
By
Region
|
- G-CSFs
(Granulocyte-colony Stimulating Factors)
- ESAs
(Erythropoiesis Stimulating Agents)
- Anti-emetics
- Bisphosphonates
- Opioids
- NSAIDs
- Others
|
- Hokkaido
- Tohoku
- Kanto
- Chubu
- Kansai
- Chugoku
- Shikoku
- Kyushu
|
Report Scope:
In this report, the Japan Cancer Supportive Care
Market has been segmented into the following categories, in addition to the
industry trends which have also been detailed below:
- Japan Cancer Supportive Care Market, By Therapeutics Class:
o G-CSFs (Granulocyte-colony Stimulating Factors)
o ESAs (Erythropoiesis Stimulating Agents)
o Anti-emetics
o Bisphosphonates
o Opioids
o NSAIDs
o Others
- Japan Cancer Supportive Care Market, By
Region:
o Hokkaido
o Tohoku
o Kanto
o Chubu
o Kansai
o Chugoku
o Shikoku
o Kyushu
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Japan
Cancer Supportive Care Market.
Available Customizations:
Japan Cancer
Supportive Care market report with the given market data, TechSci
Research offers customizations according to a company's specific needs. The
following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
Japan Cancer
Supportive Care Market is an upcoming report to be released soon. If you wish
an early delivery of this report or want to confirm the date of release, please
contact us at [email protected]